Vertex Pharmaceuticals (VRTX) Net Margin (2009 - 2026)

Vertex Pharmaceuticals' Net Margin history runs 17 years deep, the most recent figure standing at 34.53% for Q1 2026.

• In Q1 2026, Net Margin rose 1120.0% year-over-year to 34.53%; the TTM figure through Mar 2026 stood at 35.51% (up 4442.0% YoY), while the FY2025 annual figure was 32.94%, up 3780.0% from the prior year.
• Net Margin for Q1 2026 stood at 34.53%, down from 37.34% in the prior quarter.
• The five-year high for Net Margin was 41.69% in Q3 2023, with the low at 135.83% in Q2 2024.
• The 5-year median for Net Margin is 36.33% (2022), against an average of 25.55%.
• The sharpest annual moves came in 2024 and 2025: Net Margin slumped 17256 bps in 2024, then soared 17067 bps in 2025.
• Vertex Pharmaceuticals' Net Margin stood at 35.56% in 2022, then gained by 8 bps to 38.48% in 2023, then declined by 19 bps to 31.35% in 2024, then climbed by 19 bps to 37.34% in 2025, then dropped by 8 bps to 34.53% in 2026.
• Business Quant data shows VRTX's Net Margin at 34.53% in Q1 2026, 37.34% in Q4 2025, and 35.2% in Q3 2025.